Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events

Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events

Abstract Consensus guidelines exist for genotype‐guided fluoropyrimidine dosing based on variation in the gene dihydropyrimidine dehydrogenase (DPYD). However, these guidelines have not been widely implemented in North America and most studies of pretreatment DPYD screening have been conducted in Eu...

Full description

Bibliographic Details
Main Authors: Theodore J. Wigle, Brandi L. Povitz, Samantha Medwid, Wendy A. Teft, Robin M. Legan, John Lenehan, Stephanie Nevison, Veera Panuganty, Denise Keller, Jaymie Mailloux, Victoria Siebring, Sisira Sarma, Yun‐hee Choi, Stephen Welch, Eric Winquist, Ute I. Schwarz, Richard B. Kim
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.12981

Internet

https://doi.org/10.1111/cts.12981

Similar Items